Approved Uses

Otezla® (apremilast) is a prescription medicine approved for the treatment of adult patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.

Otezla is a prescription medicine approved for the treatment of adult patients with active psoriatic arthritis.

Otezla is a prescription medicine approved for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.

 
Otezla for moderate to severe
plaque psoriasis
Otezla for psoriatic arthritis
Otezla for oral ulcers
in Behçet’s Disease
SEE MORE

*Certain restrictions apply. *Certain restrictions apply; eligibility not based on income.

APPROVED USES

Otezla® (apremilast) is a prescription medicine approved for the treatment of adult patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.

Otezla is a prescription medicine approved for the treatment of adult patients with active psoriatic arthritis.

Otezla is a prescription medicine approved for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.

IMPORTANT SAFETY INFORMATION

You must not take Otezla if you are allergic to apremilast or to any of the ingredients in Otezla.

Otezla can cause severe diarrhea, nausea, and vomiting, especially within the first few weeks of treatment. Use in elderly patients and the use of certain medications with Otezla appears to increase the risk of having diarrhea, nausea, or vomiting. Tell your doctor if any of these conditions occur.

Otezla is associated with an increase in depression. In clinical studies, some patients reported depression, or suicidal behavior while taking Otezla. Some patients stopped taking Otezla due to depression. Before starting Otezla, tell your doctor if you have had feelings of depression, or suicidal thoughts or behavior. Be sure to tell your doctor if any of these symptoms or other mood changes develop or worsen during treatment with Otezla.

Some patients taking Otezla lost body weight. Your doctor should monitor your weight regularly. If unexplained or significant weight loss occurs, your doctor will decide if you should continue taking Otezla.

Some medicines may make Otezla less effective, and should not be taken with Otezla. Tell your doctor about all the medicines you take, including prescription and nonprescription medicines.

Side effects of Otezla include diarrhea, nausea, vomiting, upper respiratory tract infection, runny nose, sneezing, or congestion, abdominal pain, tension headache, and headache. These are not all the possible side effects with Otezla. Ask your doctor about other potential side effects. Tell your doctor about any side effect that bothers you or does not go away.

Tell your doctor if you are pregnant, planning to become pregnant or planning to breastfeed. Otezla has not been studied in pregnant women or in women who are breastfeeding.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-332-1088.

Please click here for Full Prescribing Information for Otezla.

All about supportplus

Otezla Support Plus

What you get with SupportPlus

$name$name

Help with insurance questions

Any insurance coverage help or assistance in working with a specialty pharmacy to get your Otezla.

$name$name

$0 Co-Pay* Program

Commercially insured patients can get Otezla for $0 per month with the Otezla $0 Co-Pay Card.

  • If approved by your health insurance plan to take Otezla, you can pay as little as $0 per month, up to an annual maximum benefit. This applies to the patient’s out-of-pocket costs, including deductible, co-insurance, and co-payments for Otezla. Patient is responsible for costs above the annual maximum. Please see the full Terms and Conditions.
  • If your health plan does not cover Otezla or requires a prior authorization, you can qualify for the Bridge to Commercial Coverage Offer and receive Otezla free for up to 12 months' supply, while pursuing approval from your health plan. No purchase necessary. Please see full Terms and Conditions.
$name$name

Assistance for the uninsured or underinsured

If you have government-issued insurance (Medicare or Medicaid) or are uninsured or underinsured, Otezla SupportPlus can put you in touch with the Amgen Safety Net Foundation, a nonprofit patient assistance program sponsored by Amgen that helps qualifying patients access Otezla and other Amgen medicines at no cost.

$name$name

24/7 nurse access

Otezla nurses are on staff 24/7, so you’ll always have someone to talk to whenever you need them.

$name$name

Resources and ongoing support

Access to helpful tools, resources, and all the information you'll need about Otezla—including the GOtezla® app to help support your treatment goals.

If you have questions, Otezla SupportPlus is here to help.

 

Prefer to do things over the phone?

You can also call 1-844-4OTEZLA (1-844-468-3952) and speak to a SupportPlus team member to enroll (available 8 am - 8 pm ET, Monday - Friday).

 

*Summary of Terms and Conditions

It is important that every patient read and understand the full Otezla® Co-Pay Card Terms and Conditions. The following summary is not a substitute for reviewing the Terms and Conditions in their entirety.

As further described below, in general:

  • The Otezla Co-Pay Card is open to patients with commercial insurance, regardless of financial need. The program is not valid for patients whose Otezla® prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs. It is not valid for cash-paying patients or where prohibited by law. (See ELIGIBILITY section below.)

With the Otezla Co-Pay Card, a commercially insured patient who meets eligibility criteria can receive one of the following two offers when filling their Otezla prescription:

  • If the patient’s health plan does not cover Otezla® (apremilast) or requires a prior authorization, a patient can receive Otezla free for up to twelve (12) prescription fills within twelve (12) months from the date of the first prescription filled under the Bridge to Commercial Coverage Offer. (See PROGRAM DETAILS section below.)
  • If Otezla is approved by the patient’s health plan, a patient can pay as little as a $0 co-pay per month for their Otezla monthly out-of-pocket costs. Monthly out-of-pocket costs include co-payment, co-insurance, and deductible out-of-pocket costs. Amgen will pay the remaining eligible out-of-pocket costs on behalf of the patient until the Amgen payments have reached either the Maximum Program Benefit or the Patient Total Program Benefit. Patients are responsible for all amounts that exceed this limit. (See PROGRAM DETAILS section below.)
  • The Otezla Co-Pay Card provides support up to the Maximum Program Benefit or Patient Total Program Benefit. If a patient’s commercial insurance plan imposes different or additional requirements on patients who receive Otezla Co-Pay Card benefits, Amgen has the right to reduce or eliminate those benefits. Whether you are eligible to receive the Maximum Program Benefit or Patient Total Program Benefit is determined by the type of plan coverage you have. Please ask your Otezla SupportPlus™ representative to help you understand eligibility for the Otezla Co-Pay Card, and whether your particular insurance coverage is likely to result in your reaching the Maximum Program Benefit, or your Patient Total Program Benefit amount, by calling 1-844-4OTEZLA (1-844-468-3952). (See PROGRAM BENEFITS section below.)

Click here to see the Otezla $0 Co-Pay Card Full Terms and Conditions.

Otezla® Co-Pay Card Terms and Conditions

I. ELIGIBILITY

Eligibility Criteria: Subject to program limitations and terms and conditions, the Otezla Co-Pay Card is open to patients who have an Otezla prescription and who have commercial or private insurance, including plans available through state and federal healthcare exchanges. This program helps eligible patients cover out-of-pocket costs related to Otezla, up to program limits. There is no income requirement to participate in this program.

This offer is not valid for patients whose Otezla prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs. It is not valid for cash-paying patients or where prohibited by law. A patient is considered cash-paying where the patient has no insurance coverage for Otezla or where the patient has commercial or private insurance but Amgen in its sole discretion determines the patient is effectively uninsured because such coverage does not provide a material level of financial assistance for the cost of an Otezla prescription.

II. PROGRAM BENEFITS

The Otezla Co-Pay Card helps provide out-of-pocket support to eligible patients for their Otezla prescription up to program limits. With the Otezla Co-Pay Card, a commercially insured patient who meets eligibility criteria can receive one of two offers when filling their Otezla prescription: the Bridge Offer or the Co-Pay Card Offer. Patients can participate in one offer at a time. See PROGRAM DETAILS for full description.

The Otezla Co-Pay Card offer does not cover out-of-pocket costs for any patient whose selected coverage option under their commercial insurance plan does not apply Otezla Co-Pay Card payments to satisfy the patient’s co-payment, deductible, or co-insurance for Otezla. Patients with these plan limitations are not eligible for the Otezla Co-Pay Card but may be eligible for other needs-based assistance provided by Amgen. These programs are often referred to as accumulator adjustment programs. If you believe your commercial insurance plan may have such limitations, please contact Otezla SupportPlus at 1-844-4OTEZLA (1-844-468-3952).

The Otezla Co-Pay Card also may provide a reduced benefit amount, unilaterally determined by Amgen in its sole discretion, to satisfy the out-of-pocket cost-sharing requirement for any patient whose plan or plan agent (including, but not limited to, a Pharmacy Benefit Manager [PBM]) requires enrollment in the Otezla Co-Pay Card as a condition of the plan or PBM waiving some or all of an otherwise applicable patient out-of-pocket cost-sharing amount. These programs are often referred to as co-pay maximizer programs. If you believe your commercial insurance plan may have such limitations, please contact Otezla SupportPlus at 1-844-4OTEZLA (1-844-468-3952). Health plans, specialty pharmacies, and Pharmacy Benefit Managers (individually and collectively “Plan Administrators”) are prohibited from enrolling patients in the Otezla Co-Pay Card. Plan Administrators are prohibited from assisting patients with enrollment in the Otezla Co-Pay Card. The patient, or his/her legal representative, must personally enroll in the Otezla Co-Pay in order to be eligible for program benefits.

If at any time a patient begins receiving prescription drug coverage under any state or government program (including but not limited to Medicare, Medicaid, TRICARE, Department of Defense, or Veteran Affairs programs), the patient will no longer be able to use this card and they must contact Otezla SupportPlus at 1-844-4OTEZLA (1-844-468-3952) (Monday through Friday, from 8AM-8PM ET) to stop their participation in this program.

Patients may not seek reimbursement for the value received from the Otezla Co-Pay Card from any third-party payers, including a flexible spending account or healthcare savings account. Participating in this program means that you are ensuring you comply with any required disclosure regarding your participation in the Otezla Co-Pay Card of your insurance carrier or Pharmacy Benefit Manager. Restrictions may apply. Offer is subject to change or discontinuation without notice. This is not health insurance.

III. PROGRAM DETAILS

With the Otezla Co-Pay Card, a commercially insured patient who meets eligibility criteria can receive one of the following two offers when filling their Otezla prescription:

Bridge to Commercial Coverage Offer

  • If the patient’s health plan does not cover Otezla® (apremilast) or requires a prior authorization, a patient can receive Otezla free for up to twelve (12) prescription fills within twelve (12) months from the date of the first prescription filled under the Bridge to Commercial Coverage Offer. (See PROGRAM DETAILS section below.)
  • Ongoing eligibility after the first three (3) fills requires that the patient has a prior authorization or medical exception denied within ninety (90) days of first use of this offer. Once insurance approval is obtained, patient is no longer eligible for this offer.
  • This is a one-time offer and patients are ineligible to re-enroll.
  • No purchase necessary. This is not health insurance. Participation is not a guarantee of insurance coverage. Valid in the United States, Puerto Rico, and the US territories. Other restrictions may apply. This offer is subject to change or discontinuation without notice.

Co-Pay Offer

  • If Otezla is approved by the patient’s health plan, a patient can pay as little as a $0 co-pay per month for their Otezla monthly out-of-pocket costs.
  • For all eligible patients, the Otezla Co-Pay Card offers:
    • A program benefit that covers the patient’s eligible out-of-pocket prescription costs for Otezla (co-pay, deductible, or co-insurance) on behalf of the patient, up to a Maximum Program Benefit determined by the program per calendar year.
    • Otezla patients can pay $0 out of pocket at the first fill and at every refill, and Amgen will pay on behalf of the patient the remaining eligible out-of-pocket prescription costs (up to the Patient Total Program Benefit described below; Otezla patients are responsible for all amounts that exceed this limit).
  • Maximum Program Benefit, Patient Total Program Benefit and Benefits May Change, End, or Vary: The program provides up to a Maximum Program Benefit of assistance to reduce a patient’s out-of-pocket prescription costs that Amgen will provide per patient for each calendar year, which must be applied to the Otezla patient’s out-of-pocket costs (co-pay, deductible, or co-insurance). Patient Total Program Benefit amounts are unilaterally determined by Amgen in its sole discretion and will not exceed the Maximum Program Benefit. The Patient Total Program Benefit may be less than the Maximum Program Benefit, depending on the terms of a patient’s prescription drug plan, and may vary among individual patients covered by different plans, based on factors determined solely by Amgen, to ensure all programs funds are used for the benefit of the patient. Each patient is responsible for costs above the Patient Total Program Benefit amounts. Please ask your Otezla SupportPlus representative to help you understand whether your particular insurance coverage is likely to result in your reaching the Maximum Program Benefit or your Patient Total Program Benefit amount by calling 1-844-4OTEZLA (1-844-468-3952) and selecting option 1. Participating patients are solely responsible for updating Amgen with changes to their prescription health insurance including, but not limited to, initiation of insurance provided by the government, the addition of any coverage terms that do not apply Otezla Co-Pay Card benefits to reduce a patient’s out-of-pocket costs, such as accumulator adjustment benefit design or a co-pay maximization program. Participating patients are responsible for providing Amgen with accurate information necessary to determine program eligibility. By accepting payments from Amgen made on behalf of participating patients, participating PBMs and Plans likewise are responsible for providing Amgen with accurate information regarding patient eligibility.
  • Patients may use the card every time they fill their Otezla prescription. Benefits reset each calendar year. Enrollment in the program is for 12 months. Patients may participate in the program for 12 months, or continue in the program after that, provided s/he continues to meet all of the program’s eligibility requirements during participation in the program, and with program enrollment renewal every 12 months. Patients can enroll/re-enroll by calling 1-844-4OTEZLA (1-844-468-3952).
 
SEE MORE

*Certain restrictions apply. *Certain restrictions apply; eligibility not based on income.

APPROVED USES

Otezla® (apremilast) is a prescription medicine approved for the treatment of adult patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.

Otezla is a prescription medicine approved for the treatment of adult patients with active psoriatic arthritis.

Otezla is a prescription medicine approved for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.

IMPORTANT SAFETY INFORMATION

You must not take Otezla if you are allergic to apremilast or to any of the ingredients in Otezla.

Otezla can cause severe diarrhea, nausea, and vomiting, especially within the first few weeks of treatment. Use in elderly patients and the use of certain medications with Otezla appears to increase the risk of having diarrhea, nausea, or vomiting. Tell your doctor if any of these conditions occur.

Otezla is associated with an increase in depression. In clinical studies, some patients reported depression, or suicidal behavior while taking Otezla. Some patients stopped taking Otezla due to depression. Before starting Otezla, tell your doctor if you have had feelings of depression, or suicidal thoughts or behavior. Be sure to tell your doctor if any of these symptoms or other mood changes develop or worsen during treatment with Otezla.

Some patients taking Otezla lost body weight. Your doctor should monitor your weight regularly. If unexplained or significant weight loss occurs, your doctor will decide if you should continue taking Otezla.

Some medicines may make Otezla less effective, and should not be taken with Otezla. Tell your doctor about all the medicines you take, including prescription and nonprescription medicines.

Side effects of Otezla include diarrhea, nausea, vomiting, upper respiratory tract infection, runny nose, sneezing, or congestion, abdominal pain, tension headache, and headache. These are not all the possible side effects with Otezla. Ask your doctor about other potential side effects. Tell your doctor about any side effect that bothers you or does not go away.

Tell your doctor if you are pregnant, planning to become pregnant or planning to breastfeed. Otezla has not been studied in pregnant women or in women who are breastfeeding.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-332-1088.

Please click here for Full Prescribing Information.

Important Safety Information

See more

You must not take Otezla if you are allergic to apremilast or to any of the ingredients in Otezla.

Otezla can cause severe diarrhea, nausea, and vomiting, especially within the first few weeks of treatment. Use in elderly patients and the use of certain medications with Otezla appears to increase the risk of having diarrhea, nausea, or vomiting. Tell your doctor if any of these conditions occur.

Sign up for support

Information about paying for Otezla

Track your progress with the free Otezla app

 

You are now leaving otezla.com and going to Facebook

The content of the linked site is the sole responsibility of the site provider. Amgen Corporation does not control or endorse this third-party website.

Click "OK" to proceed or "CANCEL" to return to otezla.com.

You are now leaving otezla.com and going to Instagram

The content of the linked site is the sole responsibility of the site provider. Amgen Corporation does not control or endorse this third-party website.

Click "OK" to proceed or "CANCEL" to return to otezla.com.

You are now leaving otezla.com and going to Youtube

The content of the linked site is the sole responsibility of the site provider. Amgen Corporation does not control or endorse this third-party website.

Click "OK" to proceed or "CANCEL" to return to otezla.com.

You are now leaving otezla.com and going to Amgen.com

Are you sure you want to do this?

You are now leaving otezla.com and going to Amgen’s “Contact Us” page

Are you sure you want to do this?

You are now leaving otezla.com and going to www.fda.gov/medwatch

The content of the linked site is the sole responsibility of the site provider. Amgen Inc. does not control or endorse this third-party website.

Click "OK" to proceed or "CANCEL" to return to otezla.com.